The glial cell modulator and phosphodiesterase inhibitor, AV411 (Ibudilast), attenuates prime- and stress-induced methamphetamine relapse
Open accessAbstract
Stress and renewed contact with drug (a "slip") have been linked to persisting relapse of methamphetamine abuse. Human brain microglial activation has been linked with methamphetamine abuse, and inhibitors of glial cell activation, certain phosphodiesterase (PDE) inhibitors, and glial cell derived neurotrophic factor (GDNF) have been reported to modulate drug abuse effects. Our objective was to determine whether the glial cell attenuator, 3-isobutyryl-2-isopropylpyrazolo-[1,5-a]pyridine (AV411, ibudilast), a non-selective PDE inhibitor and promoter of GDNF, could reduce stress- and methamphetamine prime-induced reinstatement of methamphetamine-seeking behavior. Male Long-Evans hooded rats were trained to lever press reinforced with 0.1 mg/kg i.v. methamphetamine infusion according to fixed-ratio 1 (FR1) reinforcement schedules during daily, 2-hour experimental sessions. After performance had stabilized, lever pressing was extinguished for 12 consecutive sessions and doses of 0 (vehicle), 2.5 and 7.5 mg/kg AV411 were then administered intraperitoneally b.i.d. on the last 2 days of extinction and then once on the testday to separate groups of 12 rats. During testing, the rats were given 15 min of intermittent footshock or a 1 mg/kg i.p. methamphetamine prime followed by a 2-hour reinstatement test session. AV411 significantly reduced response levels of footshock-induced (2.5 and 7.5 mg/kg) and prime-induced (7.5 mg/kg) reinstatement of extinguished methamphetamine-maintained responding. AV411 has properties consistent with the ability to attenuate relapse precipitated by stress and methamphetamine "slips" during abstinence. These results thus reinforce interest in atypical neurobiological mechanisms which could be exploited for developing novel medications for treating drug abuse disorders.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment with Ibudilast attenuates stress-induced reinstatement of extinguished methamphetamine-maintained responding.
“attenuated stress-induced reinstatement of extinguished Meth-maintained responding (Beardsley et al., 2010)”
From Stress- and Glucocorticoid-Induced Priming of Neuroinflammatory Responses: Potential Mechanisms of Stress-Induced Vulnerability to Drugs of Abuse (2011) · cites this paper as Beardsley et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Handbook of Parametric and Nonparametric Statistical Procedures
(2004) · Technometrics · doi:10.1198/tech.2004.s209 · Cited by 4,664 · see citing works
Glutamate-mediated astrocyte–neuron signalling
Parpura, V., Basarsky, T. A., Liu, F., Jeftinija, K., Jeftinija, S., & Haydon, P. G. (1994) · Nature · doi:10.1038/369744a0 · Cited by 1,737 · see citing works
Prostaglandins stimulate calcium-dependent glutamate release in astrocytes
Bezzi, P., Carmignoto, G., Pasti, L., Vesce, S., Rossi, D., Rizzini, B. L., Pozzan, T., & Volterra, A. (1998) · Nature · doi:10.1038/34651 · Cited by 1,143 · see citing works
Astrocyte-mediated potentiation of inhibitory synaptic transmission
Kang, J., Jiang, L., Goldman, S. A., & Nedergaard, M. (1998) · Nature Neuroscience · doi:10.1038/3684 · Cited by 844 · see citing works
The involvement of glial cells in the development of morphine tolerance
Song, P., & Zhao, Z.-Q. (2001) · Neuroscience Research · doi:10.1016/s0168-0102(00)00226-1 · Cited by 445 · see citing works
Role for glia in synaptogenesis
Ullian, E. M., Christopherson, K. S., & Barres, B. A. (2004) · Glia · doi:10.1002/glia.20082 · Cited by 370 · see citing works
Hutchinson, M. R., Bland, S. T., Johnson, K. W., Rice, K. C., Maier, S. F., & Watkins, L. R. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.230 · Cited by 359 · see citing works
Self-citationWatkins, L. R., Hutchinson, M. R., Ledeboer, A., Wieseler‐Frank, J., Milligan, E. D., & Maier, S. F. (2006) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2006.10.011 · Cited by 327 · see citing works
Glia: novel counter-regulators of opioid analgesia
Watkins, L. R., Hutchinson, M. R., Johnston, I. N., & Maier, S. F. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.10.001 · Cited by 327 · see citing works
Thomas, D. M., Walker, P. D., Benjamins, J. A., Geddes, T. J., & Kuhn, D. M. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.070961 · Cited by 315 · see citing works
Hutchinson, M. R., Lewis, S. S., Coats, B. D., Skyba, D. A., Crysdale, N. Y., Berkelhammer, D. L., Brzeski, A., Northcutt, A. L., Vietz, C. M., Judd, C. M., et al. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.09.012 · Cited by 301 · see citing works
Self-citationThe anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse
Shepard, J. D., Bossert, J. M., Liu, S. Y., & Shaham, Y. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.02.032 · Cited by 295 · see citing works
Nucleotide‐mediated calcium signaling in rat cortical astrocytes: Role of P2X and P2Y receptors
Fumagalli, M., Brambilla, R., D’Ambrosi, N., Volonté, C., Matteoli, M., Verderio, C., & Abbracchio, M. P. (2003) · Glia · doi:10.1002/glia.10248 · Cited by 257 · see citing works
Mizuno, T., Kurotani, T., Komatsu, Y., Kawanokuchi, J., Kato, H., Mitsuma, N., & Suzumura, A. (2003) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.009 · Cited by 226 · see citing works
Narita, M., Miyatake, M., Narita, M., Shibasaki, M., Shindo, K., Nakamura, A., Kuzumaki, N., Nagumo, Y., & Suzuki, T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301007 · Cited by 218 · see citing works
Camacho, A., & Massieu, L. (2006) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.05.014 · Cited by 206 · see citing works
Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity
LaVoie, M. J., Card, J. P., & Hastings, T. G. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.010 · Cited by 204 · see citing works
Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines
Thomas, D. M., Dowgiert, J., Geddes, T. J., Francescutti, D. M., Liu, X., & Kuhn, D. M. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.06.065 · Cited by 193 · see citing works
An astroglia-linked dopamine D2-receptor action in prefrontal cortex
Khan, Z. U., Koulen, P., Rubinstein, M., Grandy, D. K., & Goldman‐Rakic, P. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1964 · Cited by 169 · see citing works
Role for GDNF in Biochemical and Behavioral Adaptations to Drugs of Abuse
Messer, C. J., Eisch, A. J., Carlezon, W. A., Whisler, K., Shen, L., Wolf, D. H., Westphal, H., Collins, F., Russell, D., & Nestler, E. J. (2000) · Neuron · doi:10.1016/s0896-6273(00)81154-x · Cited by 166 · see citing works
Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease
Rolan, P. E., Hutchinson, M. R., & Johnson, K. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903426189 · Cited by 160 · see citing works
Self-citationDifferent glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity
Pubill, D., Canudas, A. M., Pallàs, M., Camins, A., Camarasa, J., & Escubedo, E. (2003) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0747-y · Cited by 160 · see citing works
Zhang, L., Kitaichi, K., Fujimoto, Y., Nakayama, H., Shimizu, E., Iyo, M., & Hashimoto, K. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.05.015 · Cited by 159 · see citing works
Distribution of P2X receptors on astrocytes in juvenile rat hippocampus
Kukley, M., Barden, J. A., Steinhäuser, C., & Jabs, R. (2001) · Glia · doi:10.1002/glia.1091 · Cited by 156 · see citing works
Ledeboer, A., Hutchinson, M. R., Watkins, L. R., & Johnson, K. W. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.935 · Cited by 153 · see citing works
Self-citationQi, J., Yang, J., Wang, F., Zhao, Y., Song, M., & Wu, C. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.010 · Cited by 149 · see citing works
The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family
Gibson, L. C. D., Hastings, S. F., McPhee, I., Clayton, R. A., Darroch, C. E., MacKenzie, A., MacKenzie, F. L., Nagasawa, M., Stevens, P. A., & MacKenzie, S. J. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.053 · Cited by 148 · see citing works
Anggadiredja, K., Nakamichi, M., Hiranita, T., Tanaka, H., Shoyama, Y., Watanabe, S., & Yamamoto, T. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300454 · Cited by 125 · see citing works
Guilarte, T. R., Nihei, M. K., McGlothan, J. L., & Howard, A. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00476-7 · Cited by 125 · see citing works
The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain
Ledeboer, A., Liu, T., Shumilla, J. A., Mahoney, J. H., Vijay, S., Gross, M. I., Vargas, J. A., Sultzbaugh, L., Claypool, M. D., Sanftner, L. M., et al. (2006) · Neuron Glia Biology · doi:10.1017/s1740925x0700035x · Cited by 122 · see citing works
Self-citationSuzumura, A., Ito, A., Yoshikawa, M., & Sawada, M. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01666-2 · Cited by 121 · see citing works
Fantegrossi, W. E., Woolverton, W. L., Kilbourn, M. R., Sherman, P. S., Yuan, J., Hatzidimitriou, G., Ricaurte, G. A., Woods, J. H., & Winger, G. D. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300442 · Cited by 117 · see citing works
Gervais, J., & Rouillard, C. (2000) · Synapse · doi:10.1002/(sici)1098-2396(20000315)35:4 · Cited by 109 · see citing works
Cass, W. A. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-24-08132.1996 · Cited by 99 · see citing works
Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice
Mizoguchi, H., Takuma, K., Fukakusa, A., Ito, Y., Nakatani, A., Ibi, D., Kim, H., & Yamada, K. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0955-0 · Cited by 92 · see citing works
Suppression of methamphetamine-seeking behavior by nicotinic agonists
Hiranita, T., Nawata, Y., Sakimura, K., Anggadiredja, K., & Yamamoto, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600347103 · Cited by 91 · see citing works
Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats
Escubedo, E., Guitart, L., Sureda, F. X., Jiménez, A., Pubill, D., Pallàs, M., Camins, A., & Camarasa, J. (1998) · Brain Research · doi:10.1016/s0006-8993(98)01065-8 · Cited by 79 · see citing works
Boger, H. A., Middaugh, L. D., Patrick, K. S., Ramamoorthy, S., Denehy, E. D., Zhu, H., Pacchioni, A. M., Granholm, A., & McGinty, J. F. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1067-07.2007 · Cited by 75 · see citing works
Kawanokuchi, J., Mizuno, T., Kato, H., Mitsuma, N., & Suzumura, A. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.11.007 · Cited by 73 · see citing works
Rolan, P. E., Gibbons, J. A., He, L., Chang, E., Jones, D., Gross, M. I., Davidson, J. B., Sanftner, L. M., & Johnson, K. W. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03270.x · Cited by 70 · see citing works
Self-citationBenz, B., Grima, G., & Do, K. Q. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.067 · Cited by 64 · see citing works
Moffett, M. C., & Goeders, N. E. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0625-7 · Cited by 63 · see citing works
Yan, Y., Yamada, K., Niwa, M., Nagai, T., Nitta, A., & Nabeshima, T. (2007) · The FASEB Journal · doi:10.1096/fj.06-7772com · Cited by 56 · see citing works
Niwa, M., Nitta, A., Yamada, Y., Nakajima, A., Saito, K., Seishima, M., Shen, L., Noda, Y., Furukawa, S., & Nabeshima, T. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.016 · Cited by 54 · see citing works
Tumor Necrosis Factor-α and Its Inducer Inhibit Morphine-Induced Rewarding Effects and Sensitization
Niwa, M., Nitta, A., Yamada, Y., Nakajima, A., Saito, K., Seishima, M., Noda, Y., & Nabeshima, T. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.10.009 · Cited by 50 · see citing works
Mamiya, T., Noda, Y., Ren, X., Hamdy, M. M., Furukawa, S., Kameyama, T., Yamada, K., & Nabeshima, T. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703912 · Cited by 48 · see citing works
Mori, T., Baba, J., Ichimaru, Y., & Suzuki, T. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.83.113 · Cited by 47 · see citing works
Cass, W. A., Peters, L. E., Harned, M. E., & Seroogy, K. B. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1369.024 · Cited by 44 · see citing works
Thompson, B. E., Sachs, B. D., Kantak, K. M., & Cherry, J. A. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03357.x · Cited by 40 · see citing works
Iyo, M., Bi, Y., Hashimoto, K., Inada, T., & Fukui, S. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00479-7 · Cited by 40 · see citing works
Nitta, A., Nishioka, H., Fukumitsu, H., Furukawa, Y., Sugiura, H., Shen, L., & Furukawa, S. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20258 · Cited by 37 · see citing works
Carnosine prevents methamphetamine-induced gliosis but not dopamine terminal loss in rats
Pubill, D., Verdaguer, E., Sureda, F. X., Camins, A., Pallàs, M., Camarasa, J., & Escubedo, E. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01949-0 · Cited by 35 · see citing works
Iyo, M. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00133-k · Cited by 30 · see citing works
Hamdy, M. M., Mamiya, T., Noda, Y., Sayed, M., Assi, A.-A. A., Gomaa, A. A., Yamada, K., & Nabeshima, T. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00315-6 · Cited by 30 · see citing works
Davidson, C., Gopalan, R., Ahn, C., Chen, Q., Mannelli, P., Patkar, A. A., Weese, G. D., Lee, T. H., & Ellinwood, E. H. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.056 · Cited by 28 · see citing works
Niwa, M., Nitta, A., Shen, L., Noda, Y., & Nabeshima, T. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.01.026 · Cited by 23 · see citing works
Nicotine Attenuates Relapse to Methamphetamine‐Seeking Behavior (Craving) in Rats
Hiranita, T., Anggadiredja, K., FUJISAKI, C., Watanabe, S., & Yamamoto, T. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1316.062 · Cited by 23 · see citing works
Yan, Y., Nitta, A., Mizuno, T., Nakajima, A., Yamada, K., & Nabeshima, T. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.05.029 · Cited by 22 · see citing works
Cass, W. A., Manning, M. W., & Bailey, S. L. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05190.x · Cited by 17 · see citing works
Suzuki, T., Shindo, K., Miyatake, M., Kurokawa, K., Higashiyama, K., Suzuki, M., & Narita, M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.062 · Cited by 14 · see citing works
Effect of drug-paired exteroceptive stimulus presentations on methamphetamine reinstatement in rats
Shelton, K. L., & Beardsley, P. M. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.03.028 · Cited by 11 · see citing works
Self-citationAugmented methamphetamine-induced overflow of striatal dopamine 1 day after GDNF administration
Cass, W. A., Walker, D. J., & Manning, M. W. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01314-1 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker
Yang, Z., & Wang, K. K. W. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.04.003 · Cited by 1,050 · see citing works
Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598 · see citing works
Opioid activation of Toll-Like receptor 4 contributes to drug reinforcement
Hutchinson, M., Northcutt, A., Hiranita, T., Wang, X.-H., Lewis, S. S., Thomas, J., van Steeg, K., Kopajtic, T., Loram, L., Sfregola, C., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0684-12.2012 · Cited by 279 · see citing works
Astrocytic Dysfunction and Addiction
Scofield, M. D., & Kalivas, P. W. (2014) · The Neuroscientist · doi:10.1177/1073858413520347 · Cited by 193 · see citing works
Coller, J. K., & Hutchinson, M. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.008 · Cited by 186 · see citing works
Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies
Kohno, M., Link, J., Dennis, L. E., McCready, H. D., Huckans, M. S., Hoffman, W. F., & Loftis, J. M. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.01.007 · Cited by 168 · see citing works
Neuroimmune Mechanisms of Alcohol and Drug Addiction
Cui, C., Shurtleff, D., & Harris, R. A. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801284-0.00001-4 · Cited by 163 · see citing works
Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis
Newman, A. H., Blaylock, B. L., Nader, M. A., Bergman, J., Sibley, D. R., & Skolnick, P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.06.023 · Cited by 134 · see citing works
Neuroimmune Basis of Methamphetamine Toxicity
Loftis, J. M., & Janowsky, A. J. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801284-0.00007-5 · Cited by 121 · see citing works
Ray, L. A., Bujarski, S., Shoptaw, S., Roche, D. J., Heinzerling, K., & Miotto, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.10 · Cited by 118 · see citing works
Frank, M. G., Watkins, L. R., & Maier, S. F. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.01.005 · Cited by 116 · see citing works
“Lastly, treatment with the glial inhibitor, Ibudilast (a drug used extensively in our laboratory to modulate the pro-inflammatory effects of morphine; see above), attenuated stress-induced reinstatement of extinguished Meth-maintained responding (Beardsley et al., 2010).”
BackgroundGlial cell modulators attenuate methamphetamine self-administration in therat
Snider, S. E., Hendrick, E. S., & Beardsley, P. M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.016 · Cited by 109 · see citing works
Self-citationPharmacotherapeutic agents in the treatment of methamphetamine dependence
Morley, K. C., Cornish, J. L., Faingold, A., Wood, K., & Haber, P. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313229 · Cited by 108 · see citing works
Berríos‐Cárcamo, P., Quezada, M., Quintanilla, M. E., Morales, P., Ezquer, M., Herrera‐Marschitz, M., Israel, Y., & Ezquer, F. E. (2020) · Antioxidants · doi:10.3390/antiox9090830 · Cited by 108 · see citing works
Glial and neuroinflammatory targets for treating substance use disorders
Bachtell, R. K., Jones, J. D., Heinzerling, K. G., Beardsley, P. M., & Comer, S. D. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.08.003 · Cited by 104 · see citing works
Self-citationMethamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways
Krasnova, I. N., Justinová, Z., & Cadet, J. L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4235-8 · Cited by 102 · see citing works
Cross-talk between microglia and neurons regulates HIV latency
Alvarez-Carbonell, D., Ye, F., Ramanath, N., García‐Mesa, Y., Knapp, P. E., Hauser, K. F., & Karn, J. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008249 · Cited by 93 · see citing works
Brown, K. T., Levis, S. C., O’Neill, C. E., Northcutt, A. L., Fabisiak, T., Watkins, L. R., & Bachtell, R. K. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.08.012 · Cited by 88 · see citing works
Zheng, X., Yang, J., Hou, Y., Shi, X., & Liu, K. (2024) · European journal of medical research · doi:10.1186/s40001-023-01631-4 · Cited by 88 · see citing works
Glial Modulators as Potential Treatments of Psychostimulant Abuse
Beardsley, P. M., & Hauser, K. F. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00001-9 · Cited by 82 · see citing works
Self-citationMethamphetamine induced neurotoxic diseases, molecular mechanism, and current treatment strategies
Shrestha, P., Katila, N., Lee, S., Seo, J. H., Jeong, J., & Yook, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113591 · Cited by 78 · see citing works
Potential of Glial Cell Modulators in the Management of Substance Use Disorders
Jones, J. D. (2020) · CNS Drugs · doi:10.1007/s40263-020-00721-9 · Cited by 78 · see citing works
Smith, A. C. W., Scofield, M. D., & Kalivas, P. W. (2015) · Brain Research · doi:10.1016/j.brainres.2015.03.027 · Cited by 71 · see citing works
Attarzadeh-Yazdi, G., Arezoomandan, R., & Haghparast, A. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.04.008 · Cited by 70 · see citing works
Glial mechanisms underlying substance use disorders
Linker, K. E., Cross, S. J., & Leslie, F. M. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14163 · Cited by 64 · see citing works
The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders
Mediouni, S., Marcondes, M. C. G., Miller, C. A., McLaughlin, J. P., & Valente, S. T. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01164 · Cited by 60 · see citing works
Opportunities for the Development of Neuroimmune Therapies in Addiction
Ray, L. A., Roche, D. J. O., Heinzerling, K. G., & SHOPTAW, S. J. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801284-0.00012-9 · Cited by 58 · see citing works
Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study
Worley, M. J., Heinzerling, K. G., Roche, D. J. O., & SHOPTAW, S. J. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.02.036 · Cited by 57 · see citing works
Karimi-Haghighi, S., Dargahi, L., & Haghparast, A. (2020) · Addiction Biology · doi:10.1111/adb.12740 · Cited by 56 · see citing works
Does Traumatic Brain Injury Cause Risky Substance Use or Substance Use Disorder?
Olsen, C. M., & Corrigan, J. D. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.07.013 · Cited by 55 · see citing works
Role of microglia in methamphetamine-induced neurotoxicity.
Xu, E., Liu, J., Liu, H., Wang, X., & Xiong, H. (2017) · Europe PMC (PubMed Central) · Cited by 52 · see citing works
Xu, E., Liu, J., Liu, H., Wang, X., & Xiong, H. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9780-y · Cited by 52 · see citing works
Huckans, M. S., Fuller, B. E., Chalker, A. L. N., Adams, M. K. M., & Loftis, J. M. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00178 · Cited by 49 · see citing works
Inflammatory Markers in Substance Use and Mood Disorders: A Neuroimaging Perspective
Agarwal, K., Manza, P., Chapman, M., Nawal, N., Biesecker, E., McPherson, K. L., Dennis, E., Johnson, A., Volkow, N. D., & Joseph, P. V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.863734 · Cited by 51 · see citing works
Cooper, Z. D., Jones, J. D., & Comer, S. D. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.651123 · Cited by 47 · see citing works
Li, M. J., Briones, M. S., Heinzerling, K. G., Kalmin, M. M., & SHOPTAW, S. J. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107776 · Cited by 46 · see citing works
Snider, S. E., Vunck, S. A., van den Oord, E. J. C. G., Adkins, D. E., McClay, J. L., & Beardsley, P. M. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.01.013 · Cited by 45 · see citing works
Self-citationChand, S., Gowen, A. M., Savine, M., Moore, D. Y., Clark, A. R., Huynh, W., Wu, N., Odegaard, K. E., Weyrich, L., Bevins, R. A., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12177 · Cited by 41 · see citing works
Microglia in neuroimmunopharmacology and drug addiction
Li, H., Watkins, L. R., & Wang, X. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02443-6 · Cited by 41 · see citing works
Methamphetamine-associated cognitive decline is attenuated by neutralizing IL-1 signaling
Liśkiewicz, A., Przybyła, M., Park, M., Liśkiewicz, D., Nowacka-Chmielewska, M. M., Małecki, A., Barski, J. J., Lewin‐Kowalik, J., & Toborek, M. J. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.03.016 · Cited by 38 · see citing works
Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats
Johnston, I. N., Tan, M. M. X., Cao, J., Matsos, A., Forrest, D., Si, E., Fardell, J. E., & Hutchinson, M. R. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.07.021 · Cited by 37 · see citing works
Chemokines, cytokines and substance use disorders
Ahearn, O., Watson, M. N., & Rawls, S. M. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108511 · Cited by 34 · see citing works
Jacobsen, J. H. W., Hutchinson, M. R., & Mustafa, S. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.10.010 · Cited by 32 · see citing works
Wang, H., Mei, Z. L., Zhong, K. L., Hu, M. Y., Long, Y., Miao, M. X., Li, N., Yan, T. H., & Hong, H. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.07.006 · Cited by 31 · see citing works
Heinzerling, K. G., Briones, M., Thames, A. D., Hinkin, C. H., Zhu, T., Wu, Y. N., & Shoptaw, S. J. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09883-w · Cited by 30 · see citing works
Charntikov, S., Pittenger, S. T., Thapa, I., Bastola, D. R., Bevins, R. A., & Pendyala, G. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.04.012 · Cited by 30 · see citing works
Kiebala, M., & Maggirwar, S. B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018633 · Cited by 29 · see citing works
Ibudilast for the treatment of drug addiction and other neurological conditions
Johnson, K. W., Matsuda, K., & Iwaki, Y. (2014) · Clinical Investigation · doi:10.4155/cli.14.8 · Cited by 29 · see citing works
Self-citationPhosphodiesterase 4 inhibitors and drugs of abuse: current knowledge and therapeutic opportunities
Olsen, C. M., & Liu, Q.-S. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1424-0 · Cited by 29 · see citing works
Ibudilast attenuates expression of behavioral sensitization to cocaine in male and female rats
Poland, R. S., Hahn, Y. K., Knapp, P. E., Beardsley, P. M., & Bowers, M. S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.024 · Cited by 27 · see citing works
Self-citationPharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets
Yates, J. R. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s431273 · Cited by 30 · see citing works
Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment
DeYoung, D. Z., Heinzerling, K. G., Swanson, A., TSUANG, J. W., Furst, B. A., Yi, Y., Wu, Y. N., Moody, D. E., Andrenyak, D. M., & SHOPTAW, S. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000511 · Cited by 23 · see citing works
Smiley, C. E., & Wood, S. K. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108212 · Cited by 23 · see citing works
Pittenger, S. T., Chou, S., Murawski, N. J., Barrett, S. T., Loh, O., Duque, J. F., Li, M., & Bevins, R. A. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173089 · Cited by 22 · see citing works
Nicotinic regulation of microglia: potential contributions to addiction
Soares, A. R., & Picciotto, M. R. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02703-9 · Cited by 24 · see citing works
O’Sullivan, S. J., & Schwaber, J. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.033 · Cited by 20 · see citing works
Ibudilast may improve attention during early abstinence from methamphetamine
Birath, J. B., Briones, M., Amaya, S., Shoptaw, S., Swanson, A.-N., Tsuang, J., Furst, B., Heinzerling, K., Obermeit, L., Maes, L., et al. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.05.016 · Cited by 19 · see citing works
Arezoomandan, R., Moradi, M., Attarzadeh-Yazdi, G., Tomaz, C. A. B., & Haghparast, A. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.06.011 · Cited by 19 · see citing works
Neuroinflammatory Response in Reward-Associated Psychostimulants and Opioids: A Review
Karimi‐Haghighi, S., Chavoshinezhad, S., Mozafari, R., Noorbakhsh, F., Borhani‐Haghighi, A., & Haghparast, A. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01223-6 · Cited by 19 · see citing works
Mu, L., Liu, X., Yu, H., Hu, M.-M., Friedman, V., Kelly, T. J., Zhao, L., & Liu, Q.-S. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108830 · Cited by 19 · see citing works
Davé, S., Chen, L., Yu, C., Seaton, M., Khodr, C. E., Al‐Harthi, L., & Hu, X. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14606 · Cited by 17 · see citing works
Toll-Like Receptor 4: A Novel Target to Tackle Drug Addiction?
Liu, J., Li, J., & Wu, R. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_586 · Cited by 17 · see citing works
El‐Hage, N., Rodriguez, M., Podhaizer, E. M., Zou, S., Dever, S. M., Snider, S. E., Knapp, P. E., Beardsley, P. M., & Hauser, K. F. (2014) · AIDS · doi:10.1097/qad.0000000000000291 · Cited by 16 · see citing works
Self-citationRathitharan, G., Truong, J. T., Tong, J., McCluskey, T., Meyer, J. H., Mizrahi, R., Warsh, J. J., Rusjan, P., Kennedy, J. L., Houle, S., et al. (2020) · Addiction Biology · doi:10.1111/adb.12876 · Cited by 15 · see citing works
Investigating Methamphetamine Craving Using the Extinction-Reinstatement Model in the Rat
Kufahl, P. R., & Olive, M. F. (2012) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s1-003 · Cited by 15 · see citing works
Beardsley, P. M., & Shelton, K. L. (2012) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0939s61 · Cited by 14 · see citing works
Self-citationOmidvari, S., Azimzadeh, Z., Rashnoo, F., Tahmasebinia, F., Keramatinia, A., Roozbahany, N. A., Abbaszadeh, H., & Darabi, S. (2023) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2023-2488 · Cited by 15 · see citing works
The effect of neuroimmune modulation on subjective response to alcohol in the natural environment
Meredith, L. R., Grodin, E. N., Montoya, A. K., Miranda, R., Squeglia, L. M., Towns, B., Evans, C., & Ray, L. A. (2022) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14821 · Cited by 12 · see citing works
Selective Inhibition of PDE4B Reduces Methamphetamine Reinforcement in Two C57BL/6 Substrains
Honeywell, K. M., Doren, E. V., & Szumlinski, K. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094872 · Cited by 12 · see citing works
Guo, L., Wang, Z., Lu, G.-Y., Wu, N., Dong, G.-M., Ma, C., Zhang, R., Song, R., & Li, J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172671 · Cited by 12 · see citing works
Identification of Treatment Targets in a Genetic Mouse Model of Voluntary Methamphetamine Drinking
Phillips, T. J., Mootz, J. R. K., & Reed, C. L. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.001 · Cited by 12 · see citing works
Immunotherapeutic treatment of inflammation in mice exposed to methamphetamine
Loftis, J. M., Ramani, S., Firsick, E. J., Hudson, R., Le-Cook, A., Murnane, K. S., Vandenbark, A. A., & Shirley, R. L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1259041 · Cited by 9 · see citing works
Promising immunomodulators for management of substance and alcohol use disorders
Acuña, A. M., Park, C., Leyrer‐Jackson, J. M., & Olive, M. F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2360653 · Cited by 8 · see citing works
Nicotine- and cocaine-triggered methamphetamine reinstatement in female and male Sprague-Dawley rats
Pittenger, S. T., Chou, S., Barrett, S. T., Catalano, I., Lydiatt, M. F., & Bevins, R. A. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.07.003 · Cited by 7 · see citing works
Toll-like receptor 4 antagonists reduce cocaine-primed reinstatement of drug seeking
Brown, K. T., Levis, S. C., O’Neill, C. E., Levy, C. L., Rice, K. C., Watkins, L. R., & Bachtell, R. K. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06392-w · Cited by 6 · see citing works
Therapeutic targeting of neuroinflammation in methamphetamine use disorder
Jeffery, N., Mock, P. Y., Yang, K., Tham, C. L., Israf, D. A., Li, H., Wang, X., & Lam, K. W. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2447226 · Cited by 7 · see citing works
Guida, C. R., Maia, J. M., Ferreira, L. F. R., Rahdar, A., Branco, L. G. S., & Soriano, R. N. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111070 · Cited by 6 · see citing works
Inflammatory mechanisms of abused drugs
Mitchell, C. M., Jordi, O. E., & Yamamoto, B. K. (2018) · Advances in neurotoxicology · doi:10.1016/bs.ant.2018.10.006 · Cited by 5 · see citing works
Wang, X., Cochran, T. A., Hutchinson, M. R., Yin, H. H., & Watkins, L. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1429-6_12 · Cited by 5 · see citing works
Roflumilast treatment during forced abstinence reduces relapse to methamphetamine seeking and taking
Baek, J. J., Kline, H. L., Deveau, C., & Yamamoto, B. K. (2021) · Addiction Biology · doi:10.1111/adb.13082 · Cited by 5 · see citing works
Clinical Treatment of Addictive Disorders with N-Acetylcysteine
Powell, G. L., McClure, E. A., Olive, M. F., & Gipson, C. D. (2018) · Springer eBooks · doi:10.1007/978-981-10-5311-5_13 · Cited by 4 · see citing works
Loftis, J. M., Navis, T., Taylor, J. K., Hudson, R., Shirendeb, U. P., Lattal, K. M., Vandenbark, A. A., Shirley, R. L., & Huckans, M. S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173175 · Cited by 4 · see citing works
Yang, W., Han, J., Cao, Z.-X., Yang, L., Wang, J., & Sun, T. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00169 · Cited by 3 · see citing works
Neuroimmune modulators as novel pharmacotherapies for substance use disorders
Grodin, E. N. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100744 · Cited by 3 · see citing works
Martiniaková, M., Kováčová, V., Bíro, R., Šarocká, A., Pénzes, N., Mondočková, V., & Omelka, R. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00690-3 · Cited by 2 · see citing works
Neuroglia in substance use disorders
Castro, E. M., Lotfipour, S., & Leslie, F. M. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19102-2.00014-4 · Cited by 1 · see citing works
Wu, H., Song, Z., Chen, Q., Yan, R., Zhao, H., & Li, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118037 · Cited by 1 · see citing works
Pittenger, S. T. (2016) · Lincoln (University of Nebraska) · Cited by 1 · see citing works
Therapeutic Strategies to Treat Alcohol-Related Disorders Targeting Central Immune Signaling
Wu, Y. H., & Hutchinson, M. R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4729-0_17
Snider, S. E. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/wt5e-6716
OpioidActivationofToll-LikeReceptor4Contributesto DrugReinforcement
Hutchinson, M. R., Northcutt, A. L., Hiranita, T., Wang, X., Lewis, S. S., Thomas, J., Kopajtic, T. A., Loram, L. C., Sfregola, C., Galer, E. L., et al. (2012)
Fulton, B. S. (2014) · Wiley eBooks · doi:10.1002/9781118943670.refs
Enga, R. M., Naderi, A. O., Scott, E. M., Coachman, K. D., Silva, G. M., Bergman, E. M., May, M. D., Batuure, A., Fenlon, N. S., DeMar, J. C., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103746
Nogueira, D. D. S. (2019) · theses.fr (ABES) · doi:10.70675/d429d5dbz5001z4e60z9622z4f636e667f17
The effect of neuroimmune signalling on drug addiction
Chen, Q., Chi, H., Liu, S. J., & Zhou, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1830998
Yi, Y. A. N. G., Liao, S., Zhang, T., & Jiong, L. U. O. (2026) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2026-0001
- Authors
- Beardsley, P. M., Shelton, K. L., Hendrick, E., & Johnson, K. W.
- Affiliations
- Virginia Commonwealth University (US)
- Corresponding author
- Beardsley, Patrick M.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 637
- Issue
- 1-3
- Pages
- 102-108
- ISSN
- 0014-2999 (ISSN-L)
- PMC
- PMC2878837
- OpenAlex
- W1978484881
- Cited by
- 97
- References
- 62
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 4 · 2019: 8 · 2018: 5 · 2017: 8 · 2016: 9 · 2015: 6 · 2014: 12 · 2013: 1 · 2012: 9
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01da48848-7-0-0)
- National Institute on Drug Abuse (N01 DA-4-8848, N01 DA048848, HHSN271200900027C)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- ibudilast, reinstatement of drug seeking, stress-induced relapse, footshock stress, glial activation, microglial activation, phosphodiesterase inhibitors, glial cell line-derived neurotrophic factor, drug addiction treatment, extinction
- MeSH terms
- Animals, Dose-Response Relationship, Drug, Indolizines, Injections, Intraperitoneal, Male, Methamphetamine, Neuroglia, Phosphodiesterase Inhibitors, Pyrazoles, Pyridines, Stress, Psychological, Time Factors, Amphetamine-Related Disorders, Rats, Long-Evans, Rats, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
